A

Agilent Technologies

Provides eProcurement automation and hosted catalogs

R&D Scientist - Materials Science

Full-TimeUpdated
$136.6k - $239.4k/yr+ Bonus eligibility + Stock eligibility
Senior, Expert
PhD
Santa Clara, CA, USA+1 moreMore locations: Folsom, CA, USA
In Person
Academic & Institutional ResearchPhysical Sciences
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • The role requires strong technical skills in physical and/or chemical vapor deposition and experience with materials characterization techniques, such as electron microscopy, X-ray photoelectron spectroscopy, and infrared spectroscopy.
  • A solid understanding of the physical, chemical, and mechanical behavior of materials and thin films is required.
  • A Ph.D. in Materials Science, Engineering, Physics, Chemistry, or a related field is required.
  • Experience with physical vapor deposition and/or chemical vapor deposition, including Atomic Layer Deposition, Plasma-Enhanced CVD, Metal-Organic CVD, or sputtering, is required.
  • Strong theoretical and practical knowledge of thin films and materials is required.
  • Demonstrated capability in solving sophisticated materials problems through the targeted use of characterization techniques is required.
  • Experience with multiple characterization techniques such as SEM/TEM, XPS, Auger, AFM, and FTIR is required.
  • Excellent oral and written communication skills are required.
  • Proven success in a collaborative multidisciplinary environment is required.
Responsibilities
  • Perform research and development to create novel functional coatings and integrate these coatings within current instrumentation.
  • Initiate collaborations with internal and external colleagues.
Desired Qualifications
  • Familiarity with spectroscopic analytical instrumentation, such as ICP/MS, FTIR, UV/Vis, and ICP-OES, is valuable.

About the company

A

Agilent Technologies

View
Website

Agilent Technologies provides eProcurement services that help businesses buy supplies more efficiently. It offers a suite of electronic procurement tools that let clients load their pricing into existing purchasing platforms, access a hosted catalog, and complete transactions digitally without paper. The service connects pricing data to clients’ procurement systems, delivers an online catalog, and supports automated, paperless purchasing workflows. This makes purchasing faster and reduces manual steps. Compared with competitors, Agilent emphasizes automation, quick connectivity between pricing, catalogs, and purchasing platforms, and a reliable, scalable experience backed by its broad product range. The company aims to improve client productivity and lower procurement costs, helping customers buy what they need more easily while keeping prices clear and consistent.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Get referred to Agilent Technologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q3 FY2026 revenue hit $1.88 billion, up 8.1%, and guidance rose to $7.51 billion.
  • China grew 9% and pharma grew 12%, signaling stronger end markets.
  • September 2026 launches, including S540MD and Gen5 AI, expand higher-value digital pathology.

What critics are saying

  • Tariff refunds added 110 basis points to Q3 margin, masking underlying profitability.
  • FY26 restructuring costs and workforce reductions continue through first-quarter 2027.
  • A failed pathology pivot leaves Agilent overexposed to slower instrument cycles and commoditization.

What makes Agilent Technologies unique

  • Agilent combines instruments, software, and consumables across pathology, imaging, and analytics.
  • The June 2026 Biocare Medical acquisition deepens its pathology menu and clinical reach.
  • June 2026 OpenAI and BCG collaboration pushes AI into products, operations, and workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Performance Bonus
  • Stock Options

Growth & Insights and Company News

6 month growth

3%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 28th, 2026
Agilent shares surge 54.6% to $177.58, but analysts see three reasons to hold off

Agilent shares have jumped 54.6% in six months to $177.58, helped by solid quarterly results. Analysts at StockStory still advise against buying, citing three concerns. First, sales grew at a compounded annual rate of just 3.7% over five years, below the healthcare sector standard. Second, organic revenue, which excludes acquisitions, divestitures, and currency swings, averaged 4.4% year-on-year growth over two years, slightly behind the sector. Third, return on invested capital fell by an average of 2.2 percentage points a year, which may signal fewer profitable growth opportunities. The stock trades at 26.8× forward price-to-earnings. The analysts call Agilent "not a terrible business" but see no big opportunity now.

Yahoo Finance
Oct 13th, 2026
Agilent to buy digital pathology firm Proscia for $240M in cash

Agilent Technologies Inc. agreed to buy Proscia, a digital pathology software provider, in an all-cash deal valued at $240 million at closing. Proscia's founders could earn up to $30 million more if it meets future performance milestones. Proscia's software connects slide scanners, laboratory systems, and AI tools in one platform. It serves more than 4,000 laboratories, hospitals, and clinics, and 16 of the top 20 pharmaceutical companies. Its trailing twelve-month revenue exceeds $18 million. The companies have worked together since a September 2022 distribution agreement. Agilent expects Proscia's recurring-revenue software to add a high-growth, high-margin business to its pathology portfolio. The deal is subject to customary closing conditions and is expected to close early in Agilent's fiscal year 2027.

Business Wire
Sep 29th, 2026
Agilent launches Gen5 AI cell identification module for BioTek automated imagers

Agilent Technologies has launched the BioTek Gen5 AI cell identification module, a new image analysis software add-on for its BioTek automated imaging systems. The module uses AI-based cell identification and segmentation, eliminating the need for conventional threshold setting or parameter tuning. The technology addresses challenges researchers face with threshold-based segmentation, which requires establishing and optimising analysis parameters for individual experiments. This process can introduce user-dependent variation and create difficulties in high-throughput imaging workflows. The module supports label-free and fluorescence applications, as well as live-cell and kinetic assays commonly used in life science and pharmaceutical research. It integrates with Gen5 software, allowing researchers using compatible BioTek Cytation and Lionheart automated imagers to apply AI-based segmentation within existing workflows. Agilent generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.

Yahoo Finance
Sep 19th, 2026
Agilent launches 540-slide scanner for pathology labs eyeing AI workflows

Agilent Technologies launched the S540MD slide scanner in the United States on 4 September. The FDA-cleared device can hold up to 540 glass slides at once and targets pathology labs managing high sample volumes and preparing for AI-assisted workflows. The scanner automates routine tasks and integrates with existing laboratory setups. It reached select European markets in January and is now available in Germany, the UK, France, and other European countries alongside the US. Agilent reported revenue of $1.88 billion for the quarter ended 31 July, up 8.1% year-on-year. Non-GAAP earnings per share rose 18%. Management raised full-year non-GAAP earnings guidance to $6.18 to $6.21 per share. The S540MD is a rebadged Hamamatsu NanoZoomer S540MD. Agilent has not disclosed pricing or revenue targets for the product.

Associated Press
Sep 8th, 2026
Agilent appoints ex-Stryker CFO Glenn Boehnlein to board, chair Koh Boon Hwee retires

Agilent Technologies announced that Koh Boon Hwee retired from its board of directors on 4 September 2026, after more than 20 years of service. Koh joined the board in 2003 and served as independent chair from 2017 until his retirement. Dow R. Wilson, a board member since 2018, was elected as the new chair. Wilson currently chairs the Audit and Finance Committee. The company also appointed Glenn Boehnlein to its board, effective 4 September 2026. Boehnlein spent 22 years at Stryker Corporation, serving as vice president and chief financial officer from 2016 until his retirement in 2025. He currently serves on the boards of Inogen and Sutter Health.